Patents by Inventor Jian-Min Fu

Jian-Min Fu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7919484
    Abstract: This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: April 5, 2011
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Michael D. Winther, Robert Fraser, Mikhail Chafeev, Sultan Chowdhury, Jian-Min Fu, Duanjie Hou, Shifeng Liu, Vandna Raina, Mehran Seid Bagherzadeh, Serguei Sviridov, Kashinath Sadalapure, Shaoyi Sun, Vishnumurthy Kodumuru, Nagasree Chakka, Zaihui Zhang, Melwyn Abreo, Mikhail A. Kondratenko, Daniel F. Harvey, Cindy J. Hudson, Wenbao Li, Chi Tu, Sengen Sun, Mark W. Holladay, Heinz W. Gschwend
  • Publication number: 20110009414
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise, for example, administering to a mammal in need thereof a compound of formula (II): where x, y, A, D, E, T, Q, G, Z, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (II) are also disclosed.
    Type: Application
    Filed: May 6, 2009
    Publication date: January 13, 2011
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Jian-min Fu, Vishnumurthy Kodumuru, Shifeng Liu, Kashinath Sadalapure, Nagasree Chakka, Duanjie Hou, Shaoyi Sun
  • Patent number: 7754711
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (Ia): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: July 13, 2010
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Nagasree Chakka, Mikhail Chafeev, Sultan Chowdhury, Jian-Min Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Vandna Raina, Shaoyi Sun, Serguei Sviridov, Michael D. Winther, Zaihui Zhang, Melwyn Abreo, Mark W. Holladay, Wenbao Li, Sengen Sun, Chi Tu, Heinz W. Gschwend
  • Publication number: 20090291957
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise, for example, administering to a mammal in need thereof a compound of formula (II): where x, y, A, D, E, T, Q, G, Z, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (II) are also disclosed.
    Type: Application
    Filed: May 6, 2009
    Publication date: November 26, 2009
    Applicant: Xenon Pharmaceuticals Inc.
    Inventors: Rajender Kamboj, Jian-min Fu, Vishnumurthy Kodumuru, Shifeng Liu, Kashinath Sadalapure, Nagasree Chakka, Duanjie Hou, Shaoyi Sun
  • Publication number: 20090197894
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where m, n, p, V, R1, R2, R3, R4, R5 and R6 are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: April 14, 2009
    Publication date: August 6, 2009
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Jian-Min Fu, Vishnumurthy Kodumuru, Shaoyi Sun, Michael D. Winther, Richard M. Fine, Daniel F. Harvey, Boris Klebansky, Mark P. Gray-Keller, Heinz W. Gschwend, Wenbao Li
  • Publication number: 20090131447
    Abstract: This invention is directed to the use of SCD-1 inhibitors of the formula (I): where x, y, V, W, G, J, L, M, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein, in combination with other drug therapies to treat adverse weight gain.
    Type: Application
    Filed: February 8, 2006
    Publication date: May 21, 2009
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Rajender Kamboj, Michael D. Winther, Robert Fraser, Mikhail Chafeev, Sultan Chowdhury, Jian-Min Fu, Duanjie Hou, Shifeng Liu, Vandna Raina, Mehran Seid Bagherzadeh, Serguei Sviridov, Kashinath Sadalapure, Shaoyi Sun, Vishnumurthy Kodumuru, Nagasree Chakka, Zaihui Zhang, Melwyn Abreo, Mikhail A. Kondratenko, Daniel F. Harvey, Cindy J. Hudson, Wenbao Li, Chi Tu, Sengen Sun, Mark W. Holladay, Heinz W. Gschwend
  • Publication number: 20080207587
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, G, J, K, L, M, Q, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a arc defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: September 20, 2005
    Publication date: August 28, 2008
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jian-Min Fu, Serguei Sviridov, Sultan Chowdhury, Vishnumurthy Kodumuru
  • Publication number: 20080096895
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, V R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: September 20, 2005
    Publication date: April 24, 2008
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jian-Min Fu
  • Patent number: 7335658
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Grant
    Filed: July 29, 2004
    Date of Patent: February 26, 2008
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Nagasree Chakka, Mikhail Chafeev, Sultan Chowdhury, Jian-Min Fu, Duanjie Hou, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Vandna Raina, Shaoyi Sun, Serguei Sviridov, Michael D Winther, Zaihui Zhang, Melwyn Abreo, Mark W Holladay, Wenbao Li, Sengen Sun, Chi Tu, Heinz W Gschwend
  • Publication number: 20080015230
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where y, G, K, L, M, W, V, R2, R3, R4, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: September 20, 2005
    Publication date: January 17, 2008
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Rajender Kamboj, Zaihui Zhang, Jian-Min Fu, Mehran Seid Bagherzadeh, Serguei Sviridov, Sultan Chowdhury, Shifeng Liu, Vishnumurthy Kodumuru
  • Patent number: 7291738
    Abstract: The present invention provides compounds, for example, of formula (I): wherein R1, R2, and R3 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods, and processes and intermediates useful for preparing compounds of formula I.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: November 6, 2007
    Assignee: Pharmacia & Upjohn Company
    Inventor: Jian-Min Fu
  • Publication number: 20070224636
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me.
    Type: Application
    Filed: March 24, 2006
    Publication date: September 27, 2007
    Inventor: Jian-min Fu
  • Publication number: 20070219211
    Abstract: Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise, for example, administering to a mammal in need thereof a compound of formula (I): where x, y, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
    Type: Application
    Filed: September 20, 2005
    Publication date: September 20, 2007
    Applicant: XENON PHARMACEUTICALS INC.
    Inventors: Rajender Kamboj, Jian-Min Fu, Vishnumurthy Kodumuru, Shifeng Liu, Kashinath Sadalapure, Nagasree Chakka, Duanjie Hou, Shaoyi Sun
  • Patent number: 7250418
    Abstract: The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRF1 receptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRF1 receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF1 receptors.
    Type: Grant
    Filed: May 6, 2004
    Date of Patent: July 31, 2007
    Assignee: Pfizer Inc
    Inventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
  • Patent number: 7151109
    Abstract: The present invention relates to novel pyrazolo[1,5-a]pyridine derivatives of general formula I: that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: December 19, 2006
    Assignee: Pharmacia & Upjohn Company LLC
    Inventor: Jian-Min Fu
  • Publication number: 20060217398
    Abstract: This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.
    Type: Application
    Filed: June 14, 2006
    Publication date: September 28, 2006
    Inventors: Jeffrey Corbett, Micheal Ennis, Kristine Frank, Jian-Min Fu, Robert Hoffman, Patrick Verhoest
  • Patent number: 7087617
    Abstract: This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.
    Type: Grant
    Filed: May 5, 2004
    Date of Patent: August 8, 2006
    Assignee: Pfizer Inc.
    Inventors: Jeffrey W. Corbett, Michael Dalton Ennis, Kristine E. Frank, Jian-Min Fu, Robert Louis Hoffman, Patrick R. Verhoest
  • Publication number: 20060166998
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me.
    Type: Application
    Filed: March 22, 2006
    Publication date: July 27, 2006
    Inventor: Jian-min Fu
  • Patent number: 7074791
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R1 and R2 are independently selected from H, Me or OMe.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: July 11, 2006
    Assignee: Pfizer Inc.
    Inventor: Jian-Min Fu
  • Publication number: 20060148807
    Abstract: Disclosed are novel CRF receptor antagonists and their use as treatment of a variety of disorders, including disorders manifesting hypersecretion of CRF or associated with CRF or CRF receptors, such as anxiety, and depression. CRF receptor antagonists of the invention have the structure of formula (I): including stereoisomers or mixture of stereoisomers, pharmaceutically acceptable prodrugs, or pharmaceutically acceptable salts thereof, wherein in formula (I) R is H or Me.
    Type: Application
    Filed: March 17, 2006
    Publication date: July 6, 2006
    Inventor: Jian-min Fu